Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences

Methadone and buprenorphine/naloxone medications are among the most effective treatment options for opioid use disorders, yet many people remain misinformed about their benefits and hold negative perceptions about the use of medications to treat opioid use disorders. Such perceptions, especially neg...

Full description

Saved in:
Bibliographic Details
Published in:Journal of substance abuse treatment 2022-01, Vol.132, p.108593-108593, Article 108593
Main Authors: Brousseau, Natalie M., Farmer, Heather, Karpyn, Allison, Laurenceau, Jean-Philippe, Kelly, John F., Hill, Elizabeth C., Earnshaw, Valerie A.
Format: Article
Language:English
Subjects:
Addiction
Ambivalence
Analgesics
Buprenorphine
Dropping out
Drugs
False information
Health literacy
Intervention
Methadone
Misinformation
Naloxone
Narcotics
Opioid use disorders
Opioids
Perceptions
Qualitative
Recovery
Social support
Stigma
Substance use disorder
Support groups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methadone and buprenorphine/naloxone medications are among the most effective treatment options for opioid use disorders, yet many people remain misinformed about their benefits and hold negative perceptions about the use of medications to treat opioid use disorders. Such perceptions, especially negative perceptions based on misinformation, may be especially harmful or stigmatizing within the context of disclosure (i.e., telling another about one's opioid use disorder history or treatment), inhibiting important recovery outcomes and sources of social support. Therefore, using the Disclosure Process Model as a framework, the current study seeks to characterize and compare participants' perceptions of stigmatizing reactions to their disclosures of MOUD use that stem from misinformation about methadone or buprenorphine/naloxone. Participants included people who are actively receiving MOUD as treatment. Results suggest that participants (N = 52) receiving both types of medications experienced similar stigmatizing reactions to disclosures. Participants also reported treatment consequences of misinformed reactions to their disclosure, such as dropping out of support groups (e.g., Narcotics Anonymous) or prematurely ending their medication use. Further, the paper provides participants' recommendations for avoiding or managing misinformed disclosure reactions. Short-term intervention efforts may promote strategies to manage misinformation, equipping individuals to respond to misinformation surrounding their medication use. Long-term interventions may target misinformation about methadone and buprenorphine/naloxone medications to increase health literacy, reduce stigma, and combat cultural ambivalence within communities, as well as promote recovery among people receiving medications for opioid use disorder. •Disclosing Methadone or Buprenorphine use received stigmatizing reactions.•Disclosure recipients shared similar misinformed views of medication use.•Stigmatizing reactions shaped how participants approached medication use.•Four strategies were recommended to combat misinformation surrounding medications.
ISSN:0740-5472
1873-6483
DOI:10.1016/j.jsat.2021.108593